

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
("Ascendis Health" or "the Company")



DISCLOSURE OF ACQUISITION OF SECURITIES AND DEALINGS IN SECURITIES BY ASSOCIATES OF A DIRECTOR

DISCLOSURE OF ACQUISITION OF SECURITIES

1. Shareholders are referred to the joint firm intention announcement released on the Stock Exchange News Service on Monday, 27 November 2023, regarding the potential offer by a consortium, led by ACN Capital IHC (Pty) Limited, to acquire all the shares in the Company (excluding treasury shares and shares already held by the consortium) by way of the voluntary exit offer and the delisting of Ascendis.
2. In accordance with regulation 98(3) of the Companies Regulations, 2011, as amended, ("**Regulations**"), shareholders are hereby advised that the Company has received notification from:
 - 2.1. Dendrobium Capital Proprietary Limited ("**Dendrobium**"), advising that it acquired an additional 1 265 000 ordinary shares in the issued share capital of the Company on 12 December 2023 for a maximum price per share of R0.80, following which the total of all interests held by Dendrobium in the Company amounts to 6.07% of the Company's total issued share capital, excluding treasury shares;
 - 2.2. Carl Andre Capital Proprietary Limited ("**Carl Andre Capital**"), advising that it acquired an additional 2 530 000 ordinary shares in the issued share capital of the Company on 12 December 2023 for a maximum price per share of R0.79, following which the total of all interests held by Carl Andre Capital in the Company amounts to 1.12% of the Company's total issued share capital, excluding treasury shares;
 - 2.3. Kingston Kapitaal Proprietary Limited ("**Kingston Kapitaal**"), advising that it acquired an additional 1 898 000 ordinary shares in the issued share capital of the Company on 12 December 2023 for a maximum price per share of R0.79, following which the total of all interests held by Kingston Kapitaal in the Company amounts to 2.4% of the Company's total issued share capital, excluding treasury shares; and
 - 2.4. Blee Beleggings Proprietary Limited ("**Blee Beleggings**"), advising that it acquired an additional 1 265 000 ordinary shares in the issued share capital of the Company on 12 December 2023 for a maximum price per share of R0.79, following which the total of all interests held by Blee Beleggings in the Company amounts to 1.41% of the Company's total issued ordinary share capital, excluding treasury shares;(collectively referred to as "**the Acquisitions**")
3. The requisite notice in terms of Regulation 98 has been filed with the Takeover Regulation Panel in accordance with Regulation 98(2) in respect of the Acquisitions.

DEALINGS IN SECURITIES BY ASSOCIATES OF A DIRECTOR

In compliance with paragraphs 3.63 to 3.74 of the Listings Requirements of the JSE Limited, the following information regarding the dealings in securities is disclosed:

Name of director	Carl Neethling
Name of company of which the director is a director	Ascendis Health Limited
Date of transactions	12 December 2023 (1) 12 December 2023 (2) 12 December 2023 (3) 12 December 2023 (4)
Price per security (Cents)	Low: 79 (1) High: 80 VWAP: 79.9 79 (2) 79 (3) 79 (4)
Number of securities	1 265 000 (1) 2 530 000 (2) 1 898 000 (3) 1 265 000 (4)
Total rand value of securities	R1 011 032.70 (1) R1 998 700 (2) R1 499 420 (3) R 999 350 (4)
Class of securities	Ordinary shares
Nature of transactions	Purchase of shares by an associate of the director (on-market transaction) (1) – (4)
Nature and extent of directors interest in the transactions	Indirect, beneficial (1) – (4)
Name of associates	Dendrobium Capital (1) Carl Andre Capital (2) Kingston Kapitaal (3)

	Blee Beleggings (4)
Relationship with director	<p>Director is a director of the associate and a beneficiary of a trust that is the shareholder of the associate (1)</p> <p>Director is a director of the associate and a beneficiary of a trust that is the shareholder of the associate (2)</p> <p>Director is a director of the associate (3)</p> <p>Director is a director of the associate (4)</p>

Clearance for the above was obtained in terms of paragraph 3.66 of the JSE Limited Listings Requirements.

The independent board and the board of the Company, collectively and individually, accept responsibility for the information contained in this announcement and certify that, to the best of their knowledge and belief, the information contained in this announcement accurately reflects the information contained in the TRP 98 form received by the Company and is true, and that this announcement does not omit anything that is likely to affect the importance of such information.

Johannesburg
14 December 2023

Sponsor
Valeo Capital (Pty) Ltd

